Interplay between TGF-b1 and miRNA-122 biomarkers in hepatocellular carcinoma progression in patients with chronic hepatitis C
https://doi.org/10.47665/tb.39.4.012
- Author:
Hamad, R.S.
1
;
Al Abdulsalam, N.K.
1
;
Elrefaiy, M.A.
2
;
El-Araby, R.E.
3
,
4
Author Information
1. Biological Sciences Department, College of Science, King Faisal University, Al Ahsa, Saudi Arabia&
2. Hepatoastroenterology Department, Theodor Bilharz Research Institute, Giza, Egypt
3. Central Lab, Theodor Bilharz Research Institute, Giza, Egypt&
4. Division of Oral Biology, Tufts University School of Dental Medicine, Boston, MA 02111. USA
- Publication Type:Journal Article
- Keywords:
Hepatocellular carcinoma;
TGF-b1;
MiRNA-122;
liver cirrhosis;
biomarkers
- From:Tropical Biomedicine
2022;39(No.4):559-568
- CountryMalaysia
- Language:English
-
Abstract:
Hepatocellular carcinoma (HCC) is a highly lethal malignancy and clinically validated medications have
not yet been developed since there are no reliable diagnostic and prognostic biomarkers. Based on
bioinformatics tools, TGF-b1 gene was the first target gene of miRNA-122, therefore this study was
intended to assess the potential interconnection between TGF-b1 and miRNA-122 as a diagnostic and
prognostic biomarker in the progression of HCC in patients with chronic hepatitis C (CHC) genotype
(4). In this study, 100 people were included and split into two groups; group I: CHC patients without
HCC that were classified into patients CHC without cirrhosis and CHC cirrhotic patients, group II: CHC
patients with HCC, and healthy volunteers as control. The expression of miRNA-122 and TGF-b1 genes
were analyzed using Real-Time PCR. An upregulation of miRNA-122 gene in cirrhotic and HCC patients
compared to both chronic HCV non-cirrhotic, and cirrhotic patients, while, a decrease in expression of
TGF-b1 was found in cirrhotic patients compared to HCV non-cirrhotic patients. Although significantly
downregulated in HCC patients. Regression analysis indicated that the expression levels of miRNA-122
and TGF-b1 could be regarded as important indicators of the alterations in cirrhotic and HCC patients
versus HCV non-cirrhotic patients, also with the chances of HCC versus cirrhosis patients. Our data
indicated an interaction between miRNA-122 and TGF-b1, regulated gene expression and recommended
the use of these parameters as noninvasive predictive biomarkers and therapeutic targets for HCV
induced liver cirrhosis and HCC.
- Full text:8.2022my1377.pdf
